JNJ-61803534

JNJ-61803534 is a potent, selective, and orally active small molecule inverse agonist of the nuclear receptor RORγt (retinoic acid receptor-related orphan receptor gamma t). It was developed by Janssen R&D as an anti-inflammatory agent for immune-mediated diseases. The compound inhibits RORγt-driven transcription with high selectivity over related family members (RORα and RORβ), leading to suppression of pro-inflammatory cytokines such as IL-17A, IL-17F, and IL-22 in a dose-dependent manner[1][4][7]. JNJ-61803534 advanced to Phase 1 clinical trials in healthy volunteers but its development was discontinued due to findings of fetal developmental toxicity in preclinical rabbit studies[5][6]. Its primary indication under investigation was psoriasis[2].